Biopol Chemicals MD, chairman, board of directors and AGM
NSE: BIOPOLChemicals & Petrochemicals
Share price at the NSE close on 23 Oct 2026. Previous close ₹45.85.
- Next results date: the board meets on 5 Nov 2026 to consider: financial results and other business matters.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹45 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 30 Apr 2026
- 5.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 Apr 2026
- 0.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Feb 2026
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 30 Apr 2026
- 18.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 Apr 2026
- 0.17
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 22,80068.4% delivered
Biopol Chemicals board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- M/s. M B Jajodia & AssociatesPeer-review certificate valid to Jul 2026
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Biopol Chemicals AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Biopol Chemicals share news and announcements
Annual general meeting, 22 Sep 2026
633 shareholders on the register on 18 Sep 2026; present: 1 promoter and 6 others; votes counted by CS Mansi Chokshi / M K Chokshi & Associates.The company's voting result (opens in a new tab)
To receive, consider and adopt the audited standalone financial statements of the Company for the financial year ended 31st March, 2026, together with the Reports of the Board of Directors and the Auditors thereonMoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 68.11% · promoters 100.00% · institutions 0.00% · other public 6.83%
- To appoint a Director in place of Mr. Vedant Sarkar (DIN: 10134523), who retires by rotation and, being eligible, offers himself for re-appointmentOrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 2.30% · promoters 0.00% · institutions 0.00% · other public 6.83%
- To regularise the appointment of Mr. Sukhomoy Das (DIN: 11761165) as an Independent Director (Non-Executive, Independent) of the Company for a first term of five (5) consecutive yearsSpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 68.11% · promoters 100.00% · institutions 0.00% · other public 6.83%
- To approve Material Related Party TransactionsOrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 2.30% · promoters 0.00% · institutions 0.00% · other public 6.83%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Mar 2026.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere | Reason and comments |
|---|---|---|---|---|---|---|
| Public IssuesFeb 2026 | 31.26 | Acquisition of industrial land | 12.26 | 12.26 | No | Audit committee: The committee had noted that there is no deviation/variation |
| Public IssuesFeb 2026 | 31.26 | Repayment or prepayment, in full or in part, of borrowings availed by our Company from banks, financial institutions and non-banking financial companies | 11.10 | 10.36 | No | Audit committee: The committee had noted that there is no deviation/variation |
| Public IssuesFeb 2026 | 31.26 | General Corporate Purpose | 4.04 | 4.04 | No | Audit committee: The committee had noted that there is no deviation/variation |
| Public IssuesFeb 2026 | 31.26 | Issue Related Expense | 3.85 | 3.85 | No | Audit committee: The committee had noted that there is no deviation/variation |